New clinical diagnostic procedures for cystic fibrosis in Europe

Journal of Cystic Fibrosis

Volumn 10, Issue SUPPL. 2, 2011, Pages

  De Boeck, K ^a   Derichs, N ^b   Fajac, I ^c   de Jonge, H R ^d   Bronsveld, I ^e   Sermet, I ^c   Vermeulen, F ^a   Sheppard, D N ^f   Cuppens, H ^a   Hug, M ^g   Melotti, P ^h   Middleton, P G ⁱ   Wilschanski, M ^j  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

^g UNIVERSITY OF FREIBURG   (Germany)

^h UNIVERSITY HOSPITAL OF VERONA   (Italy)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

more..

Author keywords

Electrophysiology; Genetic testing; Intestinal current measurement; Nasal potential difference

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ION; CARBACHOL; CHLORIDE; CHLORIDE CHANNEL; CYCLIC AMP; ELECTROLYTE; FORSKOLIN; HISTAMINE; INDOMETACIN; ISOPRENALINE; PILOCARPINE; POTASSIUM CHANNEL; PROSTAGLANDIN; PROSTAGLANDIN E2; SODIUM ION; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; BIOASSAY; BODY TEMPERATURE; CATHETER; CELL MEMBRANE DEPOLARIZATION; CIGARETTE SMOKING; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR BIOASSAY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE SEVERITY; DNA POLYMORPHISM; ELECTRODE; ERYTHROCYTE; EUROPE; FALSE POSITIVE RESULT; FLOW CYTOMETRY; FLUORESCENCE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; IMMUNOPRECIPITATION; INTERMETHOD COMPARISON; INTESTINAL CURRENT MEASUREMENT; ION TRANSPORT; LEUKOCYTE; MENSTRUAL CYCLE; METABOLIC INHIBITION; MISSENSE MUTATION; MULTICENTER STUDY (TOPIC); NASAL POTENTIAL DIFFERENCE; NONHUMAN; NOSE MUCOSA; OCCULT BLOOD TEST; OTOSCOPE; OUTCOME ASSESSMENT; POTENTIAL DIFFERENCE; RECORDER; RECTUM BIOPSY; RECTUM MUCOSA; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; SODIUM ABSORPTION; SQUAMOUS EPITHELIUM; SWEAT GLAND; SWEAT GLAND POTENTIAL DIFFERENCE; WESTERN BLOTTING;

CYSTIC FIBROSIS; DIAGNOSTIC TECHNIQUES, RESPIRATORY SYSTEM; EUROPE; HUMANS; MEDICINE;

EID: 79958083917     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/S1569-1993(11)60009-X     Document Type: Article

References (82)

1. De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006, 61(7):627-635.
2. Knowles MR, Paradiso AM, Boucher RC In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995, 6(4):445-455.
3. Middleton PG, Geddes DM, Alton EW Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 1994, 7(11):2050-2056.
4. Veeze HJ, Sinaasappel M, Bijman J, Bouquet J, de Jonge HR Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. Gastroenterology 1991, 101(2):398-403.
5. Mall M, Bleich M, Schurlein M, et al. Cholinergic ion secretion in human colon requires coactivation by cAMP. Am J Physiol 1998, 275(6 Pt 1):G1274-G1281.
6. Rosenstein BJ, Cutting GR The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998, 132(4):589-595.
7. LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 2007, 151(l):85-89.
8. Multi-Disciplinary Working Group Guidelines for the Performance of the Sweat Test for the Investigation of Cystic Fibrosis in the UK. 2003 http://www.acb.org.uk/docs/sweat.pdf.
9. Gibson LE, Cooke RE A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959, 23(3):545-549.
10. WHO. The molecular genetic epidemiology of cystic fibrosis. Report of a joint meeting of WHO/ECFTN/ICF(M)A/ECFS () and WHO Geneva, Human Genetics Programme WHO/HGN/CF/WG/04.02. 2004. http://www.who.int/genomics/publications/en/.
11. Castellani C, Cuppens H, Macek M, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008, 7(3):179-196.
12. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008, 153(2):S4-14.
13. Knowles MR, Carson JL, Collier AM, Gatzy JT, Boucher RC Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 1981, 124(4):484-490.
14. Wilschanski M, Famini H, Strauss-Liviatan N, et al. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001, 17(6):1208-1215.
15. Goubau C, Wilschanski M, Skalicka V, et al. Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax 2009, 64(8):683-691.
16. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008, 372(9640):719-727.
17. Gatzy JT Bioelectric properties of the isolated amphibian lung. Am J Physiol 1967, 213(2):425-431.
18. Knowles M, Gatzy J, Boucher R Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981, 305(25):1489-1495.
19. Alton EW, Hay JG, Munro C, Geddes DM Measurement of nasal potential difference in adult cystic fibrosis, Young's syndrome, and bronchiectasis. Thorax 1987, 42(10):815-817.
20. Delmarco A, Pradal U, Cabrini G, Bonizzato A, Mastella G Nasal potential difference in cystic fibrosis patients presenting borderline sweat test. Eur Respir J 1997, 10(5):1145-1149.
21. Wilschanski M, Dupuis A, Ellis L, et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006, 174(7):787-794.
22. Olivier KN, Bennett WD, Hohneker KW, et al. Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate +/- amiloride in normal human adults. Am J Respir Crit Care Med 1996, 154(l):217-223.
23. Vermeulen F, Proesmans M, Feyaerts N, De Boeck C Nasal potential measurements on the nasal floor and under the inferior turbinate: does it matter?. Pediatr Pulmonol 2011, 46(2):145-152.
24. House HH, Middleton PG Impact of different chloride and glucose solutions on nasal potential difference. Pediatr Pulmonol 2009, 44(7):645-648.
25. Yaakov Y, Kerem E, Yahav Y, et al. Reproducibility of nasal potential difference measurements in cystic fibrosis. Chest 2007, 132(4):1219-1226.
26. Leal T, Fajac I, Wallace HL, et al. Airway ion transport impacts on disease presentation and severity in cystic fibrosis. Clin Biochem 2008, 41(10-11):764-772.
27. Middleton PG, House HH Measurement of airway ion transport assists the diagnosis of cystic fibrosis. Pediatr Pulmonol 2010, 45:789-795.
28. Middleton PG, Pollard KA, Donohoo E, Wheatley JR, Geddes DM, Alton EW Airway surface liquid calcium modulates chloride permeability in the cystic fibrosis airway. Am J Respir Crit Care Med 2003, 168(10):1223-1226.
29. Middleton PG, Pollard KA, Wheatley JR Hypertonic saline alters ion transport across the human airway epithelium. Eur Respir J 2001, 17(2):195-199.
30. Boyle MP, Diener-West M, Milgram L, et al. A multicenter study of the effect of solution temperature on nasal potential difference measurements. Chest 2003, 124(2):482-489.
31. Southern KW, Noone PG, Bosworth DG, Legrys VA, Knowles MR, Barker PM A modified technique for measurement of nasal transepithelial potential difference in infants. J Pediatr 2001, 139(3):353-358.
32. Osborne LR, Lynch M, Middleton PG, et al. Nasal epithelial ion transport and genetic analysis of infertile men with congenital bilateral absence of the vas deferens. Hum Mol Genet 1993, 2(10):1605-1609.
33. Pradal U, Castellani C, Delmarco A, Mastella G Nasal potential difference in congenital bilateral absence of the vas deferens. Am J Respir Crit Care Med 1998, 158(3):896-901.
34. Bombieri C, Claustres M, De Boeck K, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 2011, 10(Suppl 2):86-102.
35. Sweezey NB, Smith D, Corey M, et al. Amiloride-insensitive nasal potential difference varies with the menstrual cycle in cystic fibrosis. Pediatr Pulmonol 2007, 42(6):519-524.
36. Cantin AM, Hanrahan JW, Bilodeau G, et al. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006, 173(10):1139-1144.
37. Davies MG, Geddes DM, Alton EW The effect of varying tonicity on nasal epithelial ion transport in cystic fibrosis. Am J Respir Crit Care Med 2005, 171(7):760-763.
38. Hebestreit A, Kersting U, Hebestreit H Hypertonic saline inhibits luminal sodium channels in respiratory epithelium. Eur J Appl Physiol 2007, 100(2):177-183.
39. Mairbaurl H, Weymann J, Mohrlein A, et al. Nasal epithelium potential difference at high altitude (4,559 m): evidence for secretion. Am J Respir Crit Care Med 2003, 167(6):862-867.
40. Thomas SR, Jaffe A, Geddes DM, Hodson ME, Alton EW Pulmonary disease severity in men with AF508 cystic fibrosis and residual chloride secretion. Lancet 1999, 353(9157):984-985.
41. Walker LC, Venglarik CJ, Aubin G, et al. Relationship between airway ion transport and a mild pulmonary disease mutation in CFTR. Am J Respir Crit Care Med 1997, 155(5):1684-1689.
42. Wallace HL, Barker PM, Southern KW Nasal airway ion transport and lung function in young people with cystic fibrosis. Am J Respir Crit Care Med 2003, 168(5):594-600.
43. Riordan JR CFTR function and prospects for therapy. Annu Rev Biochem 2008, 77:701-726.
44. Kunzelmann K, Mall M Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev 2002, 82(1):245-289.
45. Greger R Role of CFTR in the colon. Annu Rev Physiol 2000, 62:467-491.
46. Barrett KE, Keely SJ Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol 2000, 62:535-572.
47. Field M Intestinal ion transport and the pathophysiology of diarrhea. J Clin Invest 2003, 111(7):931-943.
48. Rozmahel R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 1996, 12(3):280-287.
49. Clarke LL, Grubb BR, Yankaskas JR, Cotton CU, McKenzie A, Boucher RC Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(-/-) mice. Proc Nati Acad Sci U S A 1994, 91(2):479-483.
50. De Jonge HR, Ballmann M, Veeze H, et al. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros 2004, 3(Suppl 2):159-163.
51. Bronsveld I, Mekus F, Bijman J, et al. Residual chloride secretion in intestinal tissue of ΔF508 homozygous twins and siblings with cystic fibrosis. The European CF Twin and Sibling Study Consortium. Gastroenterology 2000, 119(1):32-40.
52. Bronsveld I, Mekus F, Bijman J, et al. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of ΔF508 homozygous twins and siblings. J Clin Invest 2001, 108(11):1705-1715.
53. Hardcastle J, Hardcastle PT, Taylor CJ, Goldhill J Failure of cholinergic stimulation to induce a secretory response from the rectal mucosa in cystic fibrosis. Gut 1991, 32(9):1035-1039.
54. Mall M, Kreda SM, Mengos A, et al. The AF508 mutation results in loss of CFTR function and mature protein in native human colon. Gastroenterology 2004, 126(1):32-41.
55. Barreto C, Mall M, Amaral MD Assessment of CFTR function in native epithelia for the diagnosis of cystic fibrosis. Pediatr Pulmonol Suppl 2004, 26:243.
56. Mall M, Hirtz S, Gonska T, Kunzelmann K Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. J Cyst Fibros 2004, 3(Suppl 2):165-169.
57. Veeze HJ, Halley DJ, Bijman J, de Jongste JC, de Jonge HR, Sinaas-appel M Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype. J Clin Invest 1994, 93(2):461-466.
58. Derichs N, Bronsveld I, Mekus F, et al. Intestinal current measurement (ICM) for the diagnosis of atypical cystic fibrosis. Pediatr Pulmonol 2000, S20:91.
59. - channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004, 127(4):1085-1095.
60. Derichs N, Sanz J, von Kaenel T, et al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010, 65(7):594-599.
61. Derichs N, Mekus F, Bronsveld I, et al. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients. Pediatr Res 2004, 55(l):69-75.
62. Amaral MD, Kunzelmann K Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 2007, 28(7):334-341.
63. Derichs N, Knoll J, Hyde R, Pedemonte N, Galietta LV, Ballmann M Preclinical evaluation of CFTR modulators in ex vivo human rectal tissue. Pediatr Pulmonol 2009, 44:292.
64. Li H, Sheppard DN, Hug MJ Transepithelial electrical measurements with the Ussing chamber. J Cyst Fibros 2004, 3(Suppl 2):123-126.
65. + secretion in rectal biopsies from cystic fibrosis patients. Am J Physiol Gastrointest Liver Physiol 2000, 278(4):G617-G624.
66. al.1 (BK) channels. J Physiol 2010, 588(Pt 10):1763-1777.
67. Ma T, Thiagarajah JR, Yang H, et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002, 110(11):1651-1658.
68. Li H, Sheppard DN Therapeutic potential of cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors in polycystic kidney disease. BioDrugs 2009, 23(4):203-216.
69. Hoque KM, Woodward OM, van Rossum DB, et al. Epacl mediates protein kinase A-independent mechanism of forskolin-activated intestinal chloride secretion. J Gen Physiol 2010, 135(1):43-58.
70. Bakker R Electrophysiology of fish intestine. Transport processes Iono and Osmoregulation 1985, 240-250. Springer, New York. R. Gilles (Ed.).
71. Stanke F, Ballmann M, Bronsveld I, et al. Diversity of the basic defect of homozygous CFTR mutation genotypes in humans. J Med Genet 2008, 45(1):47-54.
72. Veeze HJ Pathophysiological aspects of cystic fibrosis: genotypes, phenotypes and Intestinal Current Measurements 1995, Erasmus University, Rotterdam.
73. Derichs N, Schuster A, Grund I, et al. Homozygosity for L997F in a child with normal clinical and chloride secretory phenotype provides evidence that this cystic fibrosis transmembrane conductance regulator mutation does not cause cystic fibrosis. Clin Genet 2005, 67(6):529-531.
74. Mayell SJ, Munck A, Craig JV, et al. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 2009, 8(1):71-78.
75. Gonska T, Ip W, Turner D, et al. Sweat gland bioelectrics differ in cystic fibrosis: a new concept for potential diagnosis and assessment of CFTR function in cystic fibrosis. Thorax 2009, 64(11):932-938.
76. Hubert D, Dusser D, Bry A, Fajac I Evaluation of a new tool for measurement of sweat chloride concentration. Pediatr Pulmonol 2009, S32:269.
77. Fajac I, Viel M, Sublemontier S, Hubert D, Bienvenu T Could a defective epithelial sodium channel lead to bronchiectasis. Respir Res 2008, 9:46.
78. Azad AK, Rauh R, Vermeulen F, et al. Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease. Hum Mutat 2009, 30(7):1093-1103.
79. Verloo P, Kocken CH, Van der Wel A, et al. Plasmodium falciparum-activated chloride channels are defective in erythrocytes from cystic fibrosis patients. J Biol Chem 2004, 279(11):10316-10322.
80. Stumpf A, Wenners-Epping K, Walte M, et al. Physiological concept for a blood based CFTR test. Cell Physiol Biochem 2006, 17(1-2):29-36.
81. McDonald TV, Nghiem PT, Gardner P, Martens CL Human lymphocytes transcribe the cystic fibrosis transmembrane conductance regulator gene and exhibit CF-defective cAMP-regulated chloride current. J Biol Chem 1992, 267(5):3242-3248.
82. Sorio C, Buffelli M, Ettorre M, et al. Functional evaluation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) expression function in human monocytes. J Cyst Fibros 2009, 8:S22.